Peptide Record

Retatrutide · Metabolic · graded 2026-07-30

Glycemic control

This grade describes how much evidence exists for Retatrutide against glycemic control — not whether it works, and not whether it is safe. It is computed from the inputs below by a fixed rule with no editorial adjustment.

Why this grade

Not hidden behind a control — showing the work is the point
Score decomposition — every input and its contribution
ComponentPointsScale
Best study type
The strongest design that produced evidence for this outcome, not the average design.
+5Human RCT 5 · Human observational 4 · Animal 2 · Preclinical 1 · None 0
Largest human sample
Largest single human study, not a pooled total across studies.
+3n ≥ 200 → 3 · 50–199 → 2 · < 50 → 1 · no human study → 0
Independent replication
Distinct research groups at the best study tier above, resolved through author and institution records.
+3≥ 3 groups → 3 · 2 → 2 · 1 → 1 · 0 → 0
Directional consistency
Share of studies at the best study tier reporting effect in the same direction — the same studies the replication row counts, not every record on the pair.
Measured over 1 stated direction across 12 studies at the best tier. A ratio over three readings and the same ratio over ninety are the same number and are not the same evidence.
0≥ 90% concordant → 3 · ≥ 70% → 2 · ≥ 50% → 1 · below → 0 · fewer than 3 readings → 0
Bias risk
A deduction, never a bonus. A flag is counted only where a record states one; silence is not a pass and is not a flag.
-2−1 per flag, floor −3: industry funding · no preregistration · no blinding
Total9Sum of the rows above, floored at 0.
What the bias row had to work with — how many of this pair’s records disclosed each field at all
FieldFlag statedStated the oppositeNot statedSilent
industry_funded
industry-funded deducts a point; declared non-commercial does not; silence does neither.
903479%
preregistered
not preregistered deducts a point; preregistered does not; silence does neither.
093479%
blinded
not blinded deducts a point; blinded does not; silence does neither.
183479%

Grade A additionally requires a total of at least 11 and replication of at least 2: a high score carried by one research group is not replicated evidence, however large the trial.

Doses administered in studies

Sourced figures, not a protocol

Studied doses — not yet collected

Dose, route and n are extracted from study full text, and full text is paywalled for most records in this corpus. No dose has been extracted for this pair yet. Read that as an extraction gap, not as evidence that the studies below administered nothing.

This is a gap in our collection, not a finding about studied doses. Read it as “we have not looked yet”, never as “there is nothing there”. How extraction works and where it fails

Cited sources

43 records · ordered by source hierarchy

These are the records the grade above was computed from — the same set, by the same rule, read from one definition shared with the grader. Records attributed to an alias for a materially different product are not among them; where this pair has any, they are listed separately below.

  • HUMAN-TRIAL12
  • ANIMAL1
  • PRECLINICAL30
SourceStudyDesignnBias flagsDate
HUMAN-TRIALEffect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722 · matched on "LY-3437943"
human-rct1250industry-funded, not blinded—
HUMAN-TRIALEffect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660 · matched on "LY-3437943"
human-rct537industry-funded—
HUMAN-TRIALEffect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603 · matched on "LY-3437943"
human-rct320industry-funded—
HUMAN-TRIALA Study of LY3437943 in Participants With Type 2 Diabetes
NCT04867785 · matched on "LY-3437943"
human-rct281industry-funded—
HUMAN-TRIALEffects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
PMID 40609566 · DOI 10.1016/s2213-8587(25)00092-0 · matched on "Retatrutide"
human-rct189industry-funded2025-08-01
HUMAN-TRIALA Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
NCT06982859 · matched on "LY-3437943"
human-rct95industry-funded—
HUMAN-TRIALA Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
NCT06982846 · matched on "LY-3437943"
human-rct80industry-funded—
HUMAN-TRIALA Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT04143802 · matched on "LY-3437943"
human-rct72industry-funded—
HUMAN-TRIALA Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
NCT04823208 · matched on "LY-3437943"
human-rct64industry-funded—
HUMAN-TRIALEfficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
PMID 42250575 · DOI 10.1016/s0140-6736(26)00967-0 · matched on "Retatrutide"
human-rct—none stated2026-06-13
HUMAN-TRIALAppetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
PMID 40916752 · DOI 10.1111/dom.70097 · matched on "Retatrutide"
human-rct—none stated2025-12-01
HUMAN-TRIALRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
PMID 37385280 · DOI 10.1016/s0140-6736(23)01053-x · matched on "Retatrutide"
human-rct—none stated2023-08-12
ANIMALComparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
PMID 39212900 · DOI 10.1007/s12020-024-03998-8 · matched on "Retatrutide"
animal—none stated2025-01-01
PRECLINICALEvaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
PMID 40988099 · DOI 10.1002/edm2.70113 · matched on "Retatrutide"
not determined66232none stated2025-09-01
PRECLINICALComparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
PMID 39968298 · DOI 10.3389/fendo.2025.1513641 · matched on "Retatrutide"
not determined9165none stated2025-01-01
PRECLINICALEfficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
PMID 40489581 · DOI 10.1210/clinem/dgaf336 · matched on "Retatrutide"
not determined2600none stated2025-09-16
PRECLINICALRationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
PMID 41160422 · DOI 10.1093/ndt/gfaf230 · matched on "Retatrutide"
not determined—none stated2026-05-29
PRECLINICALDysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
PMID 42168638 · DOI 10.1007/s00228-026-04079-7 · matched on "Retatrutide"
not determined—none stated2026-05-22
PRECLINICALMetabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.
PMID 42195239 · DOI 10.3390/medicina62050986 · matched on "Retatrutide"
not determined—none stated2026-05-18
PRECLINICALEvolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
PMID 42165732 · DOI 10.25259/ijmr_2041_2025 · matched on "Retatrutide"
not determined—none stated2026-04-01
PRECLINICALRetatrutide in type 2 diabetes mellitus and obesity: an overview.
PMID 41785010 · DOI 10.1080/17512433.2026.2642415 · matched on "LY3437943"
not determined—none stated2026-04-01
PRECLINICALPharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.
PMID 41831086 · DOI 10.1007/s11892-026-01621-w · matched on "Retatrutide"
not determined—none stated2026-03-14
PRECLINICALNovel GLP-1-based Medications for Type 2 Diabetes and Obesity.
PMID 41054801 · DOI 10.1210/endrev/bnaf036 · matched on "Retatrutide"
not determined—none stated2026-03-11
PRECLINICALMulti-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
PMID 41547240 · DOI 10.1016/j.ejmech.2026.118587 · matched on "Retatrutide"
not determined—none stated2026-03-05
PRECLINICALComparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
PMID 41787737 · DOI 10.1002/edm2.70187 · matched on "Retatrutide"
not determined—none stated2026-03-01
PRECLINICALThe role of GIP in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review.
PMID 40755350 · DOI 10.14670/hh-18-967 · matched on "LY3437943"
not determined—none stated2026-03-01
PRECLINICAL[Nephrology : what's new in 2025].
PMID 41540866 · DOI 10.53738/revmed.2026.22.945.47996 · matched on "Retatrutide"
not determined—none stated2026-01-14
PRECLINICALIUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
PMID 41478576 · DOI 10.1016/j.phrs.2025.108077 · matched on "Retatrutide"
not determined—none stated2026-01-01
PRECLINICALBeyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.
PMID 40471293 · DOI 10.1007/s00592-025-02534-y · matched on "Retatrutide"
not determined—none stated2025-09-01
PRECLINICALQuantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
PMID 39911047 · DOI 10.1089/dia.2024.0533 · matched on "Retatrutide"
not determined—none stated2025-06-01
PRECLINICALMultifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.
PMID 40081498 · DOI 10.1016/j.peptides.2025.171380 · matched on "Retatrutide"
not determined—none stated2025-05-01
PRECLINICAL[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?].
PMID 40042613 · DOI 10.1007/s00115-025-01813-x · matched on "Retatrutide"
not determined—none stated2025-05-01
PRECLINICALEfficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
PMID 38843460 · DOI 10.2337/dci24-0003 · matched on "Retatrutide"
not determined—none stated2024-11-01
PRECLINICALComparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
PMID 38976545 · DOI 10.1097/mjt.0000000000001743 · matched on "Retatrutide"
not determined—none stated2024-07-01
PRECLINICALOral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
PMID 38753454 · DOI 10.1080/14656566.2024.2356254 · matched on "Retatrutide"
not determined—none stated2024-05-01
PRECLINICALRecent advances in the treatment of type 2 diabetes mellitus using new drug therapies.
PMID 38183334 · DOI 10.1002/kjm2.12800 · matched on "Retatrutide"
not determined—none stated2024-03-01
PRECLINICALTreatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
PMID 38299476 · DOI 10.1080/14656566.2024.2311731 · matched on "Retatrutide"
not determined—none stated2024-02-01
PRECLINICALCan small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
PMID 38048046 · DOI 10.1515/jbcpp-2023-0234 · matched on "Retatrutide"
not determined—none stated2024-01-01
PRECLINICALFuture is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.
PMID 38275036 · DOI 10.2174/0115733998276832231124170324 · matched on "Retatrutide"
not determined—none stated2024-01-01
PRECLINICALThe novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
PMID 37311727 · DOI 10.1111/dom.15167 · matched on "Retatrutide"
not determined—none stated2023-09-01
PRECLINICALA new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
PMID 37385276 · DOI 10.1016/s0140-6736(23)01182-0 · matched on "Retatrutide"
not determined—none stated2023-08-12
PRECLINICALIs retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
PMID 37086147 · DOI 10.1080/13543784.2023.2206560 · matched on "LY3437943"
not determined—none stated2023-05-01
PRECLINICALPeptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.
PMID 38111116 · DOI 10.2174/0113816128279822231211101522 · matched on "Retatrutide"
not determined—none stated2023-01-01

Rows are ordered by source hierarchy, so nothing below a regulatory filing appears above a human trial. A field marked uncertain is one where the extraction passes disagreed; it publishes as unknown rather than as a picked winner. A design reading “not determined” is a design nothing established, not a design of none. Explore the full corpus for Retatrutide